Skip to content 
Application and Concentration Optimization of HPMC Binder in Sustained-Release Tablet Formulation
Hydroxypropyl Methylcellulose (HPMC) is one of the most widely used hydrophilic polymers in the pharmaceutical industry. Beyond its role as a film-former or thickener, HPMC is extensively employed as a binder and matrix-forming agent in sustained-release (SR) oral solid dosage forms. Its unique gel-forming capability upon hydration allows for controlled drug release, making it indispensable in SR tablet development.
This article explores the role of HPMC as a binder in SR formulations, focusing on how its type, viscosity grade, and concentration affect tablet integrity, drug release kinetics, and manufacturability.
1. Function of HPMC in Sustained-Release Tablets
In SR formulations, HPMC serves multiple critical functions:
Binder during granulation: ensures cohesive granule formation
Hydrophilic matrix former: forms a gel layer upon hydration to control drug release
Release modifier: adjusts drug release rate via viscosity and concentration changes
HPMC swells in aqueous environments, forming a viscous gel barrier that slows down water penetration and drug diffusion—key to achieving zero-order or near-linear release profiles.
2. Types and Grades of HPMC
HPMC is available in a wide range of viscosity grades, commonly labeled as:
| Type | Viscosity (2% solution at 20°C) | Application Notes |
|---|---|---|
| HPMC E5 / E15 | Low viscosity (5–15 mPa·s) | Used primarily as binder or film coating |
| HPMC K4M | Medium viscosity (~4,000 mPa·s) | Widely used in SR matrices |
| HPMC K15M / K100M | High viscosity (15,000–100,000 mPa·s) | Stronger gel matrix, slower release |
Selection depends on drug solubility, desired release profile, and tablet size.
3. Effect of HPMC Concentration on Tablet Performance
The concentration of HPMC in a sustained-release tablet formulation is a crucial parameter affecting:
Tablet hardness and friability
Swelling rate and gel strength
Drug release rate and profile
Typical concentration ranges in SR matrices are:
10–30% for highly soluble drugs
20–40% for moderately soluble drugs
5–15% may suffice for poorly soluble drugs when combined with other polymers
Higher HPMC levels generally provide slower drug release, but may also result in larger tablets or longer disintegration times.
4. Optimization Strategy for HPMC Concentration
To optimize HPMC concentration, formulation scientists must consider:
Drug solubility and dose: Highly soluble drugs require more polymer to sustain release
Tablet size limitations: High concentrations may increase tablet weight
Target release kinetics: Matching in vitro release with pharmacokinetic needs
Processing method: HPMC can be used in both wet granulation and direct compression
Design of Experiments (DoE) is often employed to model the effects of HPMC concentration and particle size on dissolution profiles.
5. Case Study: HPMC in Metformin SR Tablets
In a study with Metformin HCl (a highly water-soluble drug):
Using HPMC K100M at 30% w/w provided a 12-hour sustained-release profile
Lowering concentration to 20% led to faster release, failing USP requirements
Increasing above 35% did not significantly change release but affected tablet compactibility
This illustrates the need for balance between drug release control and manufacturability.
Conclusion
HPMC remains a versatile and essential excipient in sustained-release tablet formulation. Selecting the appropriate grade and concentration is key to achieving desired release kinetics, tablet quality, and processing feasibility. By understanding HPMC’s role as both a binder and matrix former, formulators can develop robust SR products that meet therapeutic and regulatory demands.